Search

Your search keyword '"Cerçel A"' showing total 18 results

Search Constraints

Start Over You searched for: Author "Cerçel A" Remove constraint Author: "Cerçel A" Publisher elsevier inc. Remove constraint Publisher: elsevier inc.
18 results on '"Cerçel A"'

Search Results

1. A multi-country analysis of COVID-19 hospitalizations by vaccination status

2. Association of Country Income Level With the Characteristics and Outcomes of Critically Ill Patients Hospitalized With Acute Kidney Injury and COVID-19

3. Thrombotic and hemorrhagic complications of COVID-19 in adults hospitalized in high-income countries compared with those in adults hospitalized in low- and middle-income countries in an international registry

4. Safety, Virologic Efficacy, and Pharmacokinetics of CT-P59, a Neutralizing Monoclonal Antibody Against SARS-CoV-2 Spike Receptor-Binding Protein: Two Randomized, Placebo-Controlled, Phase I Studies in Healthy Individuals and Patients With Mild SARS-CoV-2 Infection

6. Outcomes of Long-term Treatment of Chronic HBV Infection With Entecavir or Other Agents From a Randomized Trial in 24 Countries

9. Preclinical Development of AT1412, a Patient Derived CD9 Antibody That Does Not Induce Thrombosis for Treatment of B ALL

11. 406 – Chronic Hbv Patients Who Switched to Tenofovir Alafenamide (TAF) After Either 2 Or 3 Years of Prior Tenofovir Disoproxil Fumarate (TDF) Treatment Demonstrated Improvement in Bone and Renal Safety

14. Tu1015 MALACHITE-II: Phase 3b Trial of Ombitasvir/Paritaprevir/R and Dasabuvir + Ribavirin or Telaprevir + Peginterferon/Ribavirin in Peginterferon/Ribavirin Treatment-Experienced Adults With HCV Genotype 1

15. 1012 MALACHITE-I: Phase 3b Trial of Ombitasvir/Paritaprevir/R and Dasabuvir +/- Ribavirin or Telaprevir + Peginterferon/Ribavirin in Treatment-Naïve Adults With HCV Genotype 1

16. Su1062 Comparisons of Populations in Faldaprevir Phase III Studies Based on Pegylated Interferon α-2A and Ribavirin-Predicted Responsiveness and Impact on Achieving Svr12

17. Su1053 Virological Response in Treatment-Naïve Patients With Chronic HCV Genotype-1 Infection Receiving Faldaprevir Plus Pegylated Interferon α-2A and Ribavirin Is Unaffected by Ribavirin Dose Reduction

Catalog

Books, media, physical & digital resources